SOURCE-LINKED STUDY SUMMARY
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Abstract summarizedQuality not appraised
- What was studied
- Randomized trial comparing semaglutide with placebo, both with intensive behavioral therapy and an initial low-calorie diet.
- Who / model studied
- 611 adults with overweight or obesity and no diabetes, followed for 68 weeks; both groups received 30 counseling visits and an initial 8-week low-calorie diet.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Both primary outcomes favored semaglutide: weight fell 16.0% versus 5.7%, and 86.6% versus 47.6% lost at least 5%. For a secondary outcome, 55.8% versus 13.2% lost at least 15%. Digestive adverse events occurred in 82.8% versus 63.2%; these caused treatment withdrawal in 3.4% versus 0%.
- Limitations & context
- The authors called for further research to determine whether the findings persist over time.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jama.2021.1831